Navigation Links
PharmAthene Reports Third Quarter 2012 Financial Results
Date:11/6/2012

ANNAPOLIS, Md., Nov. 6, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial results for the third quarter ended September 30, 2012.

President and Chief Executive Officer, Eric I. Richman, said, "We made steady progress in the third quarter toward meeting our objectives. Most importantly, we have worked expeditiously to address the U.S. Food and Drug Administration's (FDA) request for additional information on our SparVax™ program, and are pleased to report that we expect to submit a complete response to the FDA shortly."

Mr. Richman continued, "Regarding the ongoing litigation with SIGA, we are now entering the final stages of the appeals process, as all legal briefs required from both PharmAthene and SIGA have been submitted to the Court and a date for oral argument has been set for January 10, 2013.  We remain confident in the merits of our case and the decision of the Delaware Court of Chancery and look forward to a final ruling from the Delaware Supreme Court no later than the second quarter of 2013."

Linda L. Chang, Senior Vice President and Chief Financial Officer, remarked, "We continue to meet our financial goals for 2012.  At the end of the third quarter of 2012 we had cash and receivables totaling approximately $20.0 million compared to $18.7 million at December 31, 2011.  Net cash used in operations year-to-date is approximately $178,000.  At this point, we are optimistic that we will be able to meet or exceed our annual cash burn goal for 2012 of $6.0 million with cash burn defined as the change in our cash and cash equivalents."

Third Quarter 2012 Financial ResultsRevenueFor the third quarter ended September 30, 2012, PharmAthene recognized revenue of $6.7 million, compare
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Reports First Quarter 2012 Financial Results
2. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
5. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
6. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
7. Patient Safety Technologies Reports Third Quarter 2012 Results
8. PDI Reports 2012 Third Quarter Financial Results
9. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... Nov. 23, 2011  Puma Biotechnology, Inc., a development stage ... the Company completed the second tranche of its $60 ... October 5, 2011, Puma sold approximately 14.7 million shares ... purchase price of $3.75 per share, resulting in gross ...
... Professor Kaustav Banerjee, a professor of electrical and ... at the University of California, Santa Barbara, has been ... the Electrostatic Discharge Association (ESDA). "The ... recognize cutting edge research ideas that advance the field ...
... Molecular diagnostics company GenturaDx announced the creation of ... three initial members: Dr. Keith Jerome, M.D., Ph.D., ... Tsongalis, Ph.D., H.C.L.D., F.A.C.B. The board will provide ... commercial market related to initial test development and ...
Cached Biology Technology:Puma Biotechnology Announces Completion of Private Placement 2Puma Biotechnology Announces Completion of Private Placement 3UCSB professor receives award for graphene electronics research 2GenturaDx Announces Formation of Scientific Advisory Board 2
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... New South Wales, Australia when NASA,s Aqua satellite passed ... July 11 (12:35 p.m. local time/11:35 p.m. EDT on ... Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spotted smoke (light brown) from various fires. Actively burning ... red. , The New South Wales, Australia Government website ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... stimulate tooth regeneration in people, according to new research ... University of Southern California (USC). For the ... USC pathology Professor Cheng-Ming Chuong, M.D., Ph.D., has uncovered ... American alligators. Their study, titled "Specialized stem cell niche ...
... Department of Biotechnology (DBT) and Bharat Biotech announced positive ... rotavirus vaccine developed and manufactured in India. Data from ... Rotavirus Vaccines for IndiaThe Evidence and the Promise, showed ... The clinical study demonstrates for the first ...
... of 70 scientists from the U.S., China, Australia and Japan ... "sacred lotus," which is believed to have a powerful genetic ... aging successfully. The scientists sequenced more than 86 percent of ... , which is revered in China and elsewhere as a ...
Cached Biology News:Alligator stem cell study gives clues to tooth regeneration 2Rotavirus vaccine developed in India demonstrates strong efficacy 2Rotavirus vaccine developed in India demonstrates strong efficacy 3Rotavirus vaccine developed in India demonstrates strong efficacy 4Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 2Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 3Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 4
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
... to meet the needs of ... component-free medium supports fast cell ... densities, while maintaining high cell ... production using the Baculovirus Expression ...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z36,327-8) or contact ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
Biology Products: